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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Over the last decades our knowledge in the field of atrial fibril-
lation (AF) has been greatly improved. Undoubtedly, double-
blinded randomized clinical trials (RCT) are the cornerstone of
high-quality, ‘‘gold standard” evidence informing optimal AF man-
agement but, owing to the RCT-specific strict enrolment criteria,
intensive monitoring and comparable study populations, the
generalisability of RCT results to everyday clinical practice may
be limited since this type of studies often does not include a broad
range of ‘‘real world” clinical settings (see Fig. 1).
Observational studies or ‘‘real world” data (RWD) complement
RCTs, providing data on much broader patient populations man-
aged in variable clinical settings, but may be limited by a selection
or information bias, hence should not be directly compared with
RCTs [1,2]. Furthermore, in some clinical circumstances, observa-
tional studies could represent the highest available level of evi-
dence [3]. Awareness of the importance and the utilization of
RWD is emerging not only in AF, but also in the area of heart failure
[4].
In general, RWD may come from several data sources such as
registries, nationwide cohorts, claims data or electronic health
records. Consistency between the RCT results and RWD enhances
the confidence in routine use of the tested treatment or interven-
tion in clinical practice. Such an example was presented by a sum-
mary of RWD data regarding safety and effectiveness of
rivaroxaban in stroke prevention among large number of patients
across the globe [5].
Indeed, RWD are also an important sources of information
about geographic differences in AF treatment [6,7]. Those dissimi-
larities can result from several reasons including regional differ-
ences in the prevalence of risk factors and/or local unmet needs
(healthcare quality or medical service availability) and knowledge
gaps.
Considering Europe in general, the EURObservational Research
Programme – Atrial Fibrillation (EORP-AF) registry and other
observational studies [8,9] showed persistently high percentage
of AF patients treated with oral anticoagulant (OAC), with a pro-
gressive increase in the use of non-vitamin K OACs. Unfortunately,
all-cause mortality rates among AF patients remain at a constant
level of 5% [10].
Several studies have reported differences in AF management
and the prevalence of guideline-adherent treatment among speci-
fic European regions. The recent insight study based on BALKAN-AF
survey on the management of patients with AF [11,12] reported
that those with newly diagnosed AF were less likely to receiveOAC in comparison to those with previously known AF (59.6%
versus 77.7%, p < 0.001, respectively) [13]. Moreover, the use of
OAC was not significantly associated with the CHA2DS2-VASc
stroke risk score and HAS-BLED bleeding risk score values. Patients
with newly diagnosed AF were more frequently administered with
single antiplatelet therapy and rhythm control medication. Treat-
ment regimen also differed among the Balkan countries depending
on healthcare system related factors and physician’s specialty.
Outside Europe, the proportion of patients on OACs is notice-
ably lower [14]. In a North-American registry of over 71,000 partic-
ipants, for example, 64.3% of AF patients in the US received OAC
[15]. Similar observations were reported in the Global Registry
on Long-Term Oral Antithrombotic Treatment in Patients with AF
(GLORIA-AF), which again indicated the highest OAC use in Europe
(90.1%) and suboptimal anticoagulation rate in Asia (55.2%) [6].
Overall, adherence to guidelines for AF management is frequently
suboptimal in everyday clinical practice. The reasons for these dif-
ferences are complex and partly unclear, possibly being influenced
by inconsistent AF treatment pathways among various specialties
managing AF patients in clinical practice, fear of complication such
as bleeding, inappropriate dosage of the drug, lack of compliance
and, at least partly, region-specific unmet needs and knowledge
gaps [7].
Are there any steps that could be taken to improve the current
situation? A recent systematic review addressing the prescription
of OACs in AF patients showed that in 15 out of 22 studies included
into the analysis, comprehensive interventions designed for
enhancing appropriate treatment administration have succeeded.
Involvement of health care professionals and patients education,
interdisciplinary medical care programs or implementation of local
guidelines were associated with substantial improvement in
guideline adherence, thus reducing the rates of AF-related stroke
and haemorrhage [16].
Another important step would be streamlining the manage-
ment of AF patients into a simplified and holistic AF treatment
pathway. Indeed, early recognition and proper management of risk
factors, symptoms and comorbidities are of the utmost importance
for AF care worldwide. The Atrial Fibrillation Better Care (ABC)
pathway for integrated care management has been proposed for
comprehensive, integrated and simple management of AF patients
[17]. It was designed to enhance the awareness and detection of AF
with subsequent step-by-step management of the arrhythmia, as
well as to facilitate patients’ understanding of the disease. The 3
steps are A = Avoid stroke (that is, identify truly low-risk patients
Fig. 1. Randomized control trials (RCT) versus ‘‘real-world” data (RWD). Abbreviations: RCT- Randomized control trial, RWD- ‘‘Real-world” data.
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CHA2DS2-VASc = 1] who do not need any antithrombotic therapy
and offer OAC to all other AF patients), B = Better symptom man-
agement (patient-centred, informed choice of rate or rhythm con-
trol therapy) and C = Cardiovascular and other risk factors and
comorbidities control. Compliance with the holistic ABC pathway
was proven to be effective and associated with improved outcomes
in several AF populations [18–20].
Although RCT are the key element in studying safety and effi-
cacy of novel clinical interventions, RWD shed light on the effec-
tiveness and safety of new treatments in a broad range of clinical
settings. Both RCT and RWD contribute to the totality of evidence
providing a better understanding of the complex challenge of
detecting and managing AF. Prospective observational registries
of AF patients from different world regions provide unique insights
into region-specific patterns of AF management, healthcare system
features and unmet needs/knowledge gaps, thus providing essen-
tial evidence informing tailored interventions directed towards
improvement of overall management of AF patients and, ulti-
mately, their outcome. Such (regional) RWD evidence is comple-
mentary to evidence from RCTs, especially since the latter may
under-represent a particular region or ethnicity. Indeed, all of us
would advocate evidence-based management, which should drive
our clinical practice, rather eminence or VIP-based opinion that
often turns a blind spot to (regional) RWD.
Appendix A. Supplementary material
Supplementary data to this article can be found online at
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